Investor Presentaiton
R&D investor presentation
Semaglutide showed numerical improvements in fibrosis and
fewer patients had progression of fibrosis vs placebo in phase 2
Semaglutide showed numerical benefits in
improvement of fibrosis without worsening of NASH¹
Proportion
of patients
100%
Fewer patients on semaglutide had progression
Proportion
of patients
30%
of fibrosis compared with placebo¹
80%
21.4%
20%
60%
47.3%
47.8%
40%
34.3%
35.9%
20%
10%
10.8%
9.4%
*
5.8%
19
0%
Placebo
0.1mg
0%
0.2mg
0.4mg
Placebo
0.1mg
0.2mg
0.4mg
Semaglutide once-daily
*Statistically significant at 72 weeks (p<0.05 vs placebo). Based on a complete case analysis using people with an evaluable biopsy at end of trial.
1 Based on a complete case analysis, using subjects with an evaluable biopsy at end of trial. Analysis included patients with fibrosis stage 1, 2, or 3 at baseline. Data is from the semaglutide
in NASH phase 2 trial.
Semaglutide once-daily
novo nordiskView entire presentation